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BACKGROUND: There is a large degree of variation in tumour response and host toxicities associated with neoadjuvant chemoradiation
for rectal cancer patients. We performed a complimentary pharmacogenetic study to investigate germline polymorphisms of genes
involved in 5-fluorouracil (5-FU) and irinotecan pathways and their potential association with clinical outcomes and toxicities from
neoadjuvant chemoradiation in patients with rectal cancer treated in a prospective genotype-directed study.
METHODS: The germline DNA of 131 patients was genotyped for 10 variants in TYMS, MTHFR, DPYD, UGT1A1, ABCC1 and SLCO1B1
genes. Ninety-six patients were treated with 5-FU/radiotherapy (RT) and 35 received 5-FU/RT/irinotecan. Relationships between
genetic variants and adverse events, tumour response, overall and disease-free survivals were assessed.
RESULTS: MTHFR 1298A4C and MTHFR diplotypes (for 677C4T and 1298A4C) were associated with chemoradiation-related
toxicity when 5-FU was used alone. MTHFR haplotypes (677C–1298C) and diplotypes (CA–TA and TA–TA) showed, respectively,
a protective and a negative effect on the incidence of severe diarrhoea or mucositis. No association was observed between genetic
markers and drug response.
CONCLUSION: MTHFR polymorphisms can potentially predict toxicity in patients treated with 5-FU as a single chemotherapeutic drug.
British Journal of Cancer (2011) 105, 1654–1662. doi:10.1038/bjc.2011.442 www.bjcancer.com
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Neoadjuvant fluoropyrimidine-based chemoradiation is currently
the standard therapy for patients with locally advanced rectal
cancer (Sauer et al, 2004; Roh et al, 2009). Preoperative treatment
was associated with lower risks of local recurrence and lower
toxicities compared with radiotherapy (RT) alone (Bosset et al,
2006; Gerard et al, 2006; Braendengen et al, 2008) or postoperative
chemoradiation CRT (Sauer et al, 2004; Roh et al, 2009).
Pathologic downstaging (DS) or a pathologic complete response
(pCR) after preoperative CRT has been correlated with improved
survival, decreased recurrence and a higher rate of sphincter-
preserving surgeries (Theodoropoulos et al, 2002; Valentini et al,
2002; Garcia-Aguilar et al, 2003; Crane et al, 2003b). The pCR and
the DS rates observed with 5-fluorouracil (5-FU)-based CRT are
10–20% (Sauer et al, 2004; Bosset et al, 2005) and B50–65%
(Garcia-Aguilar et al, 2003; Crane et al, 2003a), respectively.
The efficacy of other drugs available in colon cancer treatment,
including capecitabine (Dunst et al, 2002), oxaliplatin (Aschele
et al, 2009; Gerard et al, 2010), irinotecan (Mohiuddin et al, 2006),
cetuximab (Bertolini et al, 2009) or bevacizumab (Willett et al,
2009), has been evaluated in this setting with various results in
terms of tumour response but to date, no benefit on survival was
observed compared with the current 5-FU regimen. In the context
of multiple treatment possibilities, the identification of predictive
markers of response to chemoradiotherapy treatment is a
challenging approach for drug selection in order to obtain the
best clinical benefit while minimising the side effects for each
patient.
5-Fluorouracil is an antimetabolite of the pyrimidine analogue
type that inhibits DNA and RNA synthesis (Figure 1). Its main
mechanism of action consists of inhibition of thymidylate synthase
(TS) through an active metabolite, fluorodeoxyuridine monopho-
sphate (FdUMP), which forms an inactive ternary complex with TS
and 5–10-methylenetetrahydrofolate (MTHF). Optimal inhibition
of TS requires an elevated level of MTHF, which is regulated by
the enzyme methylenetetrahydrofolate reductase (MTHFR). As a
consequence, both TS and MTHFR activities are presumed to be
major determinants of 5-FU clinical response. Genetic polymorph-
isms with functional impact on the activity and/or expression of
both enzymes have been described.
A polymorphism within the promoter enhancer region (TSER)
of TYMS (the TS gene), consisting of tandem repeats of 28 bp,
has been implicated in modulating TS mRNA expression
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(Kaneda et al, 1987; Horie et al, 1995) and TS mRNA translational
efficiency (Kawakami et al, 2001). The most common alleles are
the double repeat (2R, TSER*2) and triple repeat (3R, TSER*3).
In vitro and in vivo studies have shown that increasing the
number of repeats (from 2R to 3R) leads to a stepwise increase in
TS expression (Horie et al, 1995; Kawakami et al, 1999; Pullarkat
et al, 2001).
TSER*3 homozygosity appears to be associated with a lower
response to neoadjuvant 5-FU-based CRT for patients with rectal
cancer (Villafranca et al, 2001; Spindler et al, 2007). Thus, we
conducted a prospective non-randomised single-institution phase
II study using TYMS genotyping to direct neoadjuvant CRT for
patients with locally advanced and metastatic rectal cancer.
Patients with germline TSER*2/*2 or TSER*2/*3, deemed ‘good
risk’ for a favourable response to 5-FU, were treated with standard
CRT. Poor-risk patients with a TSER*3/*3 or TSER*3/*4 genotypes
who were unlikely to derive significant benefit from 5-FU
chemotherapy, were treated with irinotecan in addition to
standard 5-FU/CRT. The clinical results of this study have been
published (Tan et al, 2011) and showed that patients of the poor-
risk group can achieve similar tumour DS and pCR rates to
patients of the good-risk group when irinotecan was added to the
5-FU/RT regimen. However, in each genotype/treatment group,
there was inter-individual variability in tumour response and
treatment toxicities. Several studies regarding pharmacogenetic
predictors of 5-FU pharmacodynamics have been conducted in
colorectal cancer patients with inconsistent results (Etienne et al,
2004; Ruzzo et al, 2007, 2008; Capitain et al, 2008; Gusella et al,
2009). We performed a complimentary retrospective pharmaco-
genetic study investigating germline polymorphisms of genes
involved in 5-FU and irinotecan pathways to assess their putative
role in the prediction of outcome or toxicity in rectal cancer
patients receiving 5-FU-based chemoradiation.
MATERIALS AND METHODS
Patients and treatment
All patients were included in a clinical phase II study using TYMS
genotyping to direct neoadjuvant CRT for patients with rectal
cancer (Tan et al, 2011). Patients were eligible to participate in the
study if they were 18 years old or older, with biopsy-proven clinical
T3/T4, N0-2, M0-1 adenocarcinoma of the rectum and a Karnofsky
performance status of X60%. Patients with metastatic disease,
whose primary tumours were deemed resectable, were also eligible.
Patients who qualified had adequate haematologic (absolute
neutrophil count 1500mm–3, platelets count X100 000mm–3),
renal (creatinine p2.0mg dl–1) and hepatic functions with total
bilirubin p2.0mg dl–1, SGOT and alkaline phosphatase p2
upper limit of normal. Exclusion criteria included prior pelvic
radiation, prior malignancies in the past 5 years except for skin
cancer and in situ cervical cancers and known allergy to 5-FU or
irinotecan. This study was approved by the Institutional Review
Board at Washington University School of Medicine and informed
consent was obtained from all participants before enrolment.
Before treatment, clinical staging was performed, blood samples
were obtained and TSER polymorphisms were evaluated using a
previously described PCR-based assay (Marsh et al, 1999). Patients
carrying at least one *2 allele (TSER*2/*2, *2/*3, or *2/*4) were
assigned to the good-risk genotype group (i.e. group 1) and treated
with standard preoperative CRT. Radiotherapy consisted of a total
of 45–50.4 Gy delivered in 25–28 fractions (180–200 cGy per
fraction) by a multiple field technique using image-guided
radiotherapy with radiotherapy target volume consistent with
the Radiation Therapy Oncology Group consensus guidelines
(Myerson et al, 2009). Concurrent continuous intravenous infusion
of 5-FU at a dose of 225mgm–2 per day was administered
throughout radiation without leucovorin. Patients with TSER*3/*3
or TSER*3/*4 genotypes were assigned to the poor-risk genotype
group (i.e. group 2) and treated with weekly intravenous irinotecan
at 50mgm–2 for 5 weeks in addition to standard CRT identical
to the treatment in the good-risk group. Clinical restaging and
resection of the primary rectal lesion were performed 6–10 weeks
after completion of preoperative CRT.
Evaluation of patients
Baseline clinical tumour staging, using rigid proctoscopy, trans-
rectal ultrasound (TRUS), spiral computed tomography (CT) or
magnetic resonance imaging (MRI), were performed within 28
days of enrolment. Clinical restaging with TRUS, CT or MRI was
repeated before resection. The surgical procedure performed was
at the discretion of the treating surgical oncologist. Standardised
institutional pathology examinations were done, and the patholo-
gic staging as well as the extent of residual tumour in the resected
specimen were classified using the American Joint Committee on
Cancer version 6. Tumour DS was defined as a decrease in the T
stage of the primary tumour by at least 1. Tumour complete
response (ypT0) was defined as the absence of any viable tumour
in the rectum. Toxicities were graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.
Recurrence and survival were also monitored.
Genotype analysis
Genomic DNA was isolated from whole blood using the Puregene
























Figure 1 5-Fluorouracil pathway. Abbreviations: DPD¼ dihydropyrimi-
dine dehydrogenase; FUH2¼ dihydrofluorouracil; F-UPA¼ fluoro-b-urei-
dopropionate; F-BAL¼ 5-fluoro-b-alanine; FUR¼ fluorouridine; FUMP¼
fluorouridine monophosphate; FUDP¼ fluorouridine diphosphate;
FUTP¼ fluorouridine triphosphate; FUdR¼ 5-fluorodeoxyuridine;
dUMP¼ deoxyuridine 50-monophosphate; dTMP¼ deoxythymidine
50-monophosphate; dTDP¼ deoxythymidine 50-diphosphate; dTTP¼
deoxythymidine 50-triphosphate; 5–10-CH2THF¼ 5–10-methylenetetra-
hydrofolate; 5-CH3THF¼ 5-methyltetrahydrofolate; THF¼ tetrahydro-
folate; DHF¼ dihydrofolate; MTHFR¼methylenetetrahydrolate reductase;
MS¼methionine synthetase.
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Based on previous published studies, the 5-FU-related genetic
polymorphisms selected for testing were TYMS TSER*3 G4C
(rs2853542), two intronic SNPs c.205þ 117G4C (rs2853533)
and c.280-499G4A (rs2847153), MTHFR 677C4T (rs1801133,
currently referred as c.665C4T) and 1298A4C (rs1801131,
currently referred as c.1286A4C) and DPYD*2A (rs3918290).
For irinotecan, in addition to the UGT1A1 (TA)n (rs8175347), we
genotyped samples for the UGT1A1 –3156G4A SNP (rs10929302,
currently referred as c.862-9898G4A), and two polymorphisms in
transporters, ABCC1 c.1474-48C4T (rs3765129) and SLCO1B1
c.388A4G (rs2306283) that have been described to have an effect
on irinotecan toxicity (Innocenti et al, 2009).
For TYMS TSER*3 G4C SNP, the PCR and the RFLP were
performed as described previously (Thomas et al, 2010). The
TYMS TSER*3 G4C SNP leads to a change of a critical residue in
the upstream stimulatory factor E-box consensus element
(CACTTG4CACTTC). The number of theoretical E-box-binding
sites likely to bind USF proteins was deduced based on the TYMS
G4C genotype: one E-box for genotypes 2RC/3RC or 2RC/2RG,
two E-boxes for genotypes 2RG/2RG or 2RG/3RC or 3RC/3RC or
2RC/3RG, three E-boxes for 2RG/3RG or 3RC/3RG, four E-boxes
for 3RG/3RG or 2RG/4R or 3RC/4R and five E-boxes for 3RG/4R.
TYMS genotypes with p2 E-boxes were classified as ‘low
expression of TS’ and X3 were classified as ‘high expression of
TS’ as proposed by Kawakami and Watanabe (2003).
Genotypes for TYMS c.205þ 117G4C, TYMS c.280-499G4A
and SLCO1B1*1b 388A4G were determined using allelic dis-
crimination with TaqMan SNP Genotyping assays (Applied
Biosystems, Foster City, CA, USA) C_26612339_10 and
C_1637481_10 and C_1901697_20, respectively.
Genotyping for MTHFR 667C4T, MTHFR 1298A4C, DPY-
D*2A, UGT1A1 (TA)n and UGT1A1 –3156G4A were determined
using pyrosequencing as previously described (Marsh et al, 2005;
McLeod et al, 2010). ABCC1 IVS11 –48C4T was genotyped
using pyrosequencing (Marsh et al, 2005) with the following
primers: biotinylated-forward 50-AGCATGGTGAAACCCATCT-30;
reverse 50-TCAGCTTGATCCGATTGTCTT-30 and sequencing 50-G
GGCGACCCTGGGAT-30.
Statistics
Each SNP was tested for deviation from Hardy–Weinberg
equilibrium. Since not all SNPs are biallelic, binomial expansions
of the equation were used to compute expected values. w2 tests of
association were used if the expected value of each cell was 45,
and Fisher’s exact tests were used when the cells were too sparse.
Additionally, tests for deviation from Hardy–Weinberg propor-
tions were performed two ways: first on the entire cohort (n¼ 131)
and second on Caucasian samples only (n¼ 111, other racial
groups did not have enough individuals for stratified analysis).
Relationships between genetic variants and the incidence of
grade 3–4 toxicity, tumour response (measured by DS and ypT0
rates), overall and disease-free survivals were assessed.
The association analyses were performed for each genotype
variable, using categorical genotypic encodings. For each genotype
variable and outcome combination, traditional tests of hypotheses
were performed based on the data types in the model, and whether
the data met parametric assumptions. When possible, parametric
tests were performed to increase power, and non-parametric tests
were used when statistical assumptions were not met. Contingency
table analyses and proportional hazards analyses were used for the
categorical outcomes and time-to-event outcomes, respectively.
When significant associations were found, corresponding odds
ratios (ORs) and their 95% confidence intervals (95% CIs) were
calculated. Permutation tests were performed to correct
for multiple testing for each outcome leading to different cutoff
P-values for each outcome. Additionally, multiple logistic regres-
sion analysis was performed for each of the four outcomes against
the different treatments using both markers and treatment as
factor. The model was logit(y)¼ interceptþmarkerþ treatmentþ
marker treatment. If no significant results were seen in the
multiple regression analyses, details are not shown. Analysis
was performed in Stata v.11 (StataCorp LP, College Station, TX,
USA; http://www.stata.org) and R (http://www.r-project.org and
http://cran.r-project.org/doc/FAQ/R-FAQ.html). Haplotypes were
determined with Shape-IT, publicly available at http://www.griv.
org/shapeit/ (Delaneau et al, 2008).
RESULTS
Patients and treatment outcome
There were 131 patients treated and evaluable for assessment of
toxicity, overall survival (OS) and recurrence-free survival (RFS)
(both considered as intent to treat). Among the 131 patients, 96
were assigned to group 1 based on their TYMS TSER genotype and
were treated with 5-FUþRT and 35 were in the group 2 and were
treated with 5-FUþRTþ irinotecan. As shown in Table 1, a total
of 10 patients were inevaluable for tumour DS and ypT0
evaluation, mostly for surgery issues. The clinical results have
been previously published (Tan et al, 2011) and are summarised in
Table 1. Briefly, in group 1, the DS and ypT0 rates were 64.4%
and 20%, respectively. Grade 3 or 4 toxicities occurred in 30.2% of
patients.
In group 2, which was treated with 5-FUþRTþ irinotecan, 19 of
the 35 (54.3%) patients experienced grade 3–4 toxicities and
the DS and ypT0 rates were 64.5% and 41.9%, respectively. To
assess the impact of the genotype on treatment-specific toxicity,
the existence of grade 3/4 diarrhoea and/or mucositis has been
considered together for patients treated with 5-FUþRT (Table 1).
Genotyping
The genotyping results are presented in Table 2. For the TYMS
TSER*3 G4C SNP, five alleles were identified: 2RC, 2RG, 3RC,
3RG and 4R. Among the patients carrying the 3RC allele, two
displayed an unexpected size of the 3R allele that was due to a 6-bp
insertion (CCCCCG) in the second repeat of the 3R allele. This
particular finding has been recently reported (Thomas et al, 2010).
For the current pharmacogenetic study, these two patients have
been considered as carrying the 3RC allele because their small
number did not allow studying them separately. Genotypes were










Total number of patients 96 35
Number of evaluable patients for
DS and ypT0 90 31
Overall and relapse-free survivals 96 35
Toxicity 96 35
Tumour DS 58 (64.4%) 20 (64.5%)
ypT0 18 (20%) 13 (41.9%)
3-year overall survival 78.2% 83.6%
3-year relapse-free survival 70.7% 68.4%
Grade 3–4 toxicity 29 (30.2%) 19 (54.3%)
Grade 3–4 diarrhoea
and/or mucositis
21 (21.9%) 16 (45.7%)
Abbreviations: DS¼ downstaging; ypT0¼ tumour complete response; 5-FU¼
5-fluorouracil.
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first grouped based on the number of E-boxes (as shown in
Table 2) and then into ‘low expression’ vs ‘high expression’ of TS
for statistical analyses. It is noteworthy that the repartition of these
genotypes is biased in each group since the groups have been
created based on the TYMS TSER polymorphism (*2/*2þ *2/
*3þ *2/*4 vs *3/*3þ *3/*4). No DPYD*2A variant was identified in
the studied cohort of patients. The observed genotypes were
in agreement with the Hardy–Weinberg equilibrium in the
Caucasian population. The resulting P-values from these tests are
shown in Table 2 for the 111 Caucasians out of the 131 patients.
Haplotypes for MTHFR 677C4T and 1298A4C were also
analysed. Four haplotype identities were observed; although the TC
haplotype had a very low frequency (0.38%) compared with CA
(35.9%), CC (32.4%) and TA (31.3%) haplotypes. Linkage
disequilibrium was weak between these two SNPs with r2¼ 0.27
in Caucasians, which is similar to that reported in the HapMap
Table 2 Genotype and allele frequencies for the genetic polymorphisms tested
Patients
Allele frequency in





n¼ 35 p q
HWE P-valuea
in Caucasians
TYMS 3R G4C (number of E-boxes)
2RC/2RG or 2RC/3RC (1) 3 0 2RG: 0.450 40.99
2RC/3RG or 2RG/2RG or 2RG/3RC or 3RC/3RC (2) 60 12 2RC: 0.015
2RG/3RG or 3RG/3RC (3) 32 17 3RG: 0.225
2RG/4R or 3RC/4R or 3RG/3RG (4) 1 5 3RC: 0.298
3RG/4R (5) 0 1 4R: 0.012
TYMS c.280-499G4A




GG 68 20 0.68













(TA)5/(TA)6 0 1 0.50
(TA)5/(TA)7 3 0 (TA)5: 0.015
(TA)6/(TA)6 42 16 (TA)6: 0.664
(TA)6/(TA)7 41 14 (TA)7: 0.298

















GG 96 35 1.00 0.00 40.99
GA 0 0
AA 0 0
Abbreviations: HWE¼Hardy–Weinberg equilibrium; MTHFR¼methylenetetrahydrofolate reductase. aCalculated with Fisher’s exact test, except for TYMS 3R G4C and
UGT1A1(TA)nTAA that were calculated with w
2 test. The P-values reported are uncorrected for multiple comparisons.
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Caucasian population (r2¼ 0.22), and r2¼ 0.20 in all patients
(http://hapmap.ncbi.nlm.nih.gov/).
Genetic polymorphisms and drug response to 5-FU
Drug response was assessed with four variables: tumour DS, ypT0,
OS and RFS. The following genetic markers were tested for
associations with drug response: TYMS 3R G4C SNP, the number
of TYMS E-boxes, TS expression, the two intronic TYMS SNPs
(rs2847153 and rs2853533), MTHFR 677C4T, and 1298A4C,
MTHFR diplotype for 677C4T and 1298A4C and MTHFR
haplotypes. The analyses were first performed in the group 1 to
assess the impact of genetic markers on response to 5-FU alone. All
markers except those regarding the TSER region of TYMS (TYMS
3R G4C SNP, the number of TYMS E-boxes and the TS
expression) were also tested in the whole group (n¼ 131)
representing a mix of patients treated with 5-FU alone or in combi-
nation with irinotecan. None of the genotypes was significantly
associated with drug response in group 1 or the whole group.
Genetic polymorphisms and 5-FU toxicity
The same genetic markers were tested for associations with 5-FU
toxicity in group 1. By considering the general grade 3–4 toxicity,
one MTHFR diplotype (CA–TA) was significantly related to a
higher rate of grade 3–4 toxic events (P¼ 0.006). The MTHFR
genotypes, haplotypes and diplotypes were then analysed with
regards to 5-FU-specific toxicity such as diarrhoea and mucositis.
The results are presented in Table 3 and Figure 2. The MTHFR
1298A4C genotype was significantly associated with grade 3–4
diarrhoea and/or mucositis (P¼ 0.005), with patients with the A/A
genotype having a higher risk of toxicity (OR¼ 4.71; 95%
CI¼ 1.63, 13.59) compared to patients with the A/C or C/C
genotype (Figure 2A). Although not significant, the 677C/C
genotype tended to be protective from G3–4 diarrhoea and/or
mucositis, as shown in Figure 2B. Consistent with these results, the
MTHFR CC (677C–1298C) haplotype was associated with a lower
incidence of G3–4 diarrhoea and/or mucositis (Figure 2D;
P¼ 0.005; OR¼ 0.21; 95% CI¼ 0.074, 0.61). The MTHFR diplotype
showed that the patients carrying the CA–TA and TA–TA
diplotypes had a higher risk (OR¼ 7.75; 95% CI¼ 2.67, 22.47) of
developing grade 3–4 diarrhoea and/or mucositis (P¼ 0.003; see
Figure 2C). These relationships between MTHFR markers and
grade 3–4 diarrhoea and/or mucositis were not observed in group
2, which was treated with 5-FUþRTþ irinotecan.
Genetic polymorphisms and drug response to
5-FUþ irinotecan
Associations between UGT1A1 (TA)n, UGT1A1 –3156G4A,
SLCO1B1*1b 388A4G and ABCC1 IVS11 –48C4T genotypes and
drug response (tumour DS, ypT0, OS and RFS) to 5-FUþ irinotecan
were evaluated for the 35 patients of group 2. None of these markers
was significantly associated with drug response.
Genetic polymorphisms and 5-FUþ irinotecan toxicity
The impact of UGT1A1 (TA)n, UGT1A1 –3156G4A, SLCO1B1*1b
388A4G and ABCC1 IVS11 –48C4T genotypes was evaluated
on toxicity related to 5-FUþ irinotecan, for example, in the 35
patients of group 2. None of these markers was associated with
grade 3–4 overall toxicity.
DISCUSSION
The main finding of this study is that MTHFR polymorphisms are
associated with 5-FU-specific toxicity when 5-FU is used alone.
Patients carrying the 1298A/A genotype have a higher risk of
developing grade 3–4 diarrhoea or mucositis compared to patients
with the A/C or C/C genotype when treated with 5-FU alone but
this risk was not observed in patients treated with 5-FU and
Table 3 Associations between MTHFR genotypes, haplotypes and diplotypes and grade 3–4 diarrhoea and/or mucositis
Group 1 Group 2




Number of patients (%)
with G3–4 diarrhoea
and/or mucositis,
N¼ 21 (22%) P-valuea









CC 34 (87) 5 (13) 12 (57) 9 (43)
CT 34 (74) 12 (26) 0.138 6 (46) 7 (54) 0.851
TT 7 (64) 4 (36) 1 (100) 0 (0)
MTHFR 1298A4C
AA 26 (63) 15 (37) 9 (53) 8 (47)
AC 41 (91) 4 (9) 0.005 9 (60) 6 (40) 0.699
CC 8 (80) 2 (20) 1 (33) 2 (67)
MTHFR haplotype
677C–1298A 33 (73) 12 (27) 0.329 15 (58) 11 (42) 0.700
677C–1298C 49 (89) 6 (11) 0.005 10 (56) 8 (44) 40.99
677T–1298A 40 (71) 16 (29) 0.080 7 (50) 7 (50) 0.739
MTHFR diplotype
CA–CA 13 (87) 2 (13) 0.003 4 (50) 4 (50) 0.766
CA–CC 14 (93) 1 (7) 7 (70) 3 (30)
CA–TA 6 (40) 9 (60) 4 (50) 4 (50)
CC–CC 7 (78) 2 (22) 1 (33) 2 (66)
CC–TA 27 (90) 3 (10) 2 (40) 3 (60)
CC–TC 1 (100) 0 (0) 0 0
TA–TA 7 (64) 4 (36) 1 (100) 0 (0)
Abbreviation: MTHFR¼methylenetetrahydrofolate reductase. aBased on the permutation test, the P-value cutoff for significance was 0.009. The significant P-values are shown in
bold cases. The P-values reported are uncorrected for multiple comparisons.
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irinotecan. By considering the MTHFR haplotypes, we observed
that only 10% of the patients carrying the 677C–1298C haplotype
experienced grade 3–4 diarrhoea or mucositis compared with 36%
of patients with other haplotypes, suggesting that the CC haplotype
confers a protective effect. Consistent with these observations, two
MTHFR diplotypes CA–TA and TA–TA (homozygous wild type
for 1298A4C and at least one variant allele for 677C4T) were
predictive of a higher rate of grade 3–4 diarrhoea or mucositis.
Opposite findings have been published by Capitain et al (2008),
regarding the role of MTHFR 1298A4C polymorphism on 5-FU
toxicity in colorectal patients. They found that homozygosity for
MTHFR 1298C/C confers a higher risk of grade 3–4 toxic events.
However, the effect of this polymorphism was not assessed on
toxicity such as diarrhoea or mucositis and the percentage of
patients undergoing serious toxic events was lower than in the
present study. Moreover, the regimen used in their study included
leucovorin whereas the patients in our study did not receive
leucovorin in combination with 5-FU. This raises the question of
the results inconsistency regarding the role of MTHFR poly-
morphisms as predictive markers of treatment outcome and
toxicity that has been published in colorectal patients (De Mattia
and Toffoli, 2009). It is hypothesised that MTHFR polymorphisms
may augment the cytotoxic activity of 5-FU by increasing
intracellular concentrations of 5,10-methylentetrahydrofolate and
then enhancing the formation and stability of the ternary
inhibitory complex (Bagley and Selhub, 1998; Weisberg et al,
1998). MTHFR 1298C and 677T variants are then theoretically
associated with a higher cytotoxicity. The trend we observed for
677T being associated with a higher incidence of grade 3–4
diarrhoea or mucositis is in agreement with this hypothesis; on the
contrary, the association observed between MTHFR 1298A variant
and toxicity is opposite to what was expected. However, most of
the studies investigating the role of MTHFR polymorphisms in
colorectal patients treated with fluoropyrimidine-based che-
motherapy have yielded conflicting results (reviewed in De Mattia
and Toffoli, 2009). Among the reasons for these inconsistencies,
we can mention the variety of drugs (oxaliplatin, irinotecan, etc.)
co-administered with the fluoropyrimidine, different clinical
settings (adjuvant, neoadjuvant, first- and second-line palliative
chemotherapy), the route of administration for 5-FU (bolus and
infusion) and finally the addition of leucovorin. All these factors
might influence the associations between MTHFR polymorphisms
and fluoropyrimidine activity.
Our study represents an ideal situation for investigating the role
of MTHFR polymorphisms in 5-FU outcome because (i) 5-FU was
given as monotherapy in group 1; (ii) no leucovorin was added to
the 5-FU regimen; therefore, the pool of methylenetetrahydrofolate
was directly controlled by MTHFR (see Figure 1); (iii) 5-FU
cytoxicity, when given as a continuous infusion, has been shown to
rely more on inhibition of TS activity and DNA synthesis than
RNA inhibition (Tsujinaka et al, 1992; Noordhuis et al, 2004); and
(iv) patients were chemonaive, which excludes the possibility
of acquired resistance to chemotherapy. For patients treated
with chemoradiation using irinotecan and 5-FU, the association of
MTHFR genotype and toxicity could not be clearly defined. This
can be due to the very small sample size (n¼ 35) but we can
hypothesise that the effect of MTHFR polymorphisms on 5-FU
toxicity is abrogated when irinotecan is added to the regimen.
Indeed, the leading cause of diarrhoea observed in group 2 is
certainly irinotecan and, therefore, seems independent on MTHFR.
More so, the incidence of grade 3–4 diarrhoea was high (45.7%)
among patients treated with irinotecan-based chemoradiation,
compared with 17.7% among those treated with 5-FU alone in our
prospective study (Tan et al, 2011). This difference in toxicity
between the two treatment groups may abrogate the effect MTHFR
on toxicity among irinotecan-treated patients. Moreover, due to
the trial design, groups 1 and 2 differ also from each other in terms
of TYMS genotype. Therefore, we cannot exclude that the
difference observed between the two groups for MTHFR effect
may be due to TYMS genotype and not to different therapies.
This is the first study investigating the role of pharmacogenetics
in 5-FU toxicity in rectal cancer while two studies have already
looked at the influence of these genetic markers on drug response




























































































Figure 2 Relationships between incidence of grade 3–4 diarrhoea and/or mucositis experienced by patients treated with 5-FU/RT (group 1) with MTHFR
1298A4C genotype (A), MTHFR 677C4T genotype (B), MTHFR diplotype (C) and MTHFR CC haplotype (D).
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showed that patients with the MTHFR 667T–1298A haplotype had
a lower tumour regression rate compared with other haplotypes.
However, among the 125 patients investigated, 25% received 5-FU
as a bolus and only 36% were treated with 5-FU alone. More
recently, Balboa et al (2010) found no relationship between
MTHFR polymorphisms and tumour response, which is in
agreement with our findings. The impact of MTHFR polymorph-
isms has also been evaluated on capecitabine toxicity in breast
cancer patients (Largillier et al, 2006) and colorectal patients
(Sharma et al, 2008). Although the first study did not identify
any associations between MTHFR polymorphisms and toxicity,
Sharma et al (2008) showed that the MTHFR 677T/T and 1298A/A
genotypes were associated with a lower incidence of grade 2–3
overall toxicity, which is not in agreement with our findings. They
also identified MTHFR diplotypes (CA–CC and CC–TA) that
conferred a higher risk of toxicity. In our analysis, these diplotypes
were not predictive of a higher incidence of toxicity. Among
potential explanations for these discrepancies, we can mention that
capecitabine, despite being an oral prodrug of 5-FU, presents some
differences with 5-FU in the safety profile (e.g. lower incidence of
stomatitis and diarrhoea, higher incidence of hand foot syndrome)
(Cassidy et al, 2002). Also, in our study, we tested genotype
associations with grade 3–4 toxicity whereas Sharma et al (2008)
considered grade 2–3 toxic events because of low incidence of
toxicity from capecitabine.
TYMS polymorphisms were not identified as predictive markers
of drug response and toxicity in our study but it may be due to its
design. Indeed, group 1 (treated with 5-FUþRT) was only
composed of patients with TSER*2/*2 or TSER*2/*3 genotypes,
which decreased the incidence of the TSER*3 G4C SNP in this
group and then probably the range of TS activity. On the other
hand, patients carrying the TSER*3/*3 genotype and thereby being
more susceptible to carry the TSER*3 G4C SNP were included in
group 2 and treated with 5-FUþRTþ irinotecan. The addition of
irinotecan increased the incidence of grade 3–4 adverse events and
in particular diarrhoea. Thus, the addition of irinotecan to the
regimen is a confounding factor and complicates the identification
of relationships between the TYMS TSER*3 G4C SNP and 5-FU
response or toxicity. For this reason, it is not possible to draw any
conclusion regarding the lack of significant relationships between
TYMS polymorphisms and 5-FU outcome from our study.
Regarding the pharmacogenetics of irinotecan, none of the
genetic markers investigated was significantly associated with
irinotecan toxicity and response. The low dose of irinotecan used
in this regimen (i.e. 50mgm–2) and the small number of patients
treated (n¼ 35) might explain the lack of associations observed
(Hoskins et al, 2007). Indeed, homozygosity for UGT1A1*28 has
been clearly identified as a risk factor for developing severe
irinotecan-induced neutropenia, while heterozygous patients
seem at intermediate risk (Kim and Innocenti, 2007). Innocenti
et al (2009) showed that irinotecan-induced neutropenia can be
explained in part by the UGT1A1*93, ABCC1 IVS11 –48C4T and
SLCO1B1*1b 388A4C genetic polymorphisms, but in their
study, irinotecan was administered at considerably higher doses
(300–350mgm–2); therefore, it is not surprising that we could not
reproduce these associations.
In summary, our results suggest that MTHFR genetic poly-
morphisms (particularly MTHFR 1298A4C and diplotype) are
predictive for grade 3–4 diarrhoea or mucositis when 5-FU is
administered as a single agent but not in combination
with irinotecan. These findings need to be validated in a larger
cohort and the results obtained in the group treated with
5-FUþ irinotecan should be interpreted with caution for small
sample size and confounding factors. Our study demonstrates that
pharmacogenetic–pharmacodynamics studies require certain
homogeneity in the selection of patients and therapy and that
the presence of concomitant chemotherapeutic agents (such as
irinotecan in this study) may confound the results by participating
in the global pharmacodynamic events.
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